Brian J Sandri1, Laia Masvidal2, Carl Murie2, Margarita Bartish2,3, Svetlana Avdulov1, LeeAnn Higgins4, Todd Markowski4, Mark Peterson1, Jonas Bergh3, Ping Yang5, Charlotte Rolny3, Andrew H Limper6, Timothy J Griffin4, Peter B Bitterman1, Chris H Wendt1,7, Ola Larsson2. 1. 1Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. 2. 2Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. 3. 3Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. 4. 4Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota. 5. 5Department of Epidemiology and. 6. 6Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota; and. 7. 7Pulmonary, Allergy, Critical Care, and Sleep Medicine, Veterans Affairs Medical Center, Minneapolis, Minnesota.
Abstract
Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis. Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer. Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.
Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis. Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer. Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results:Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.
Authors: Anthony J Trimboli; Carmen Z Cantemir-Stone; Fu Li; Julie A Wallace; Anand Merchant; Nicholas Creasap; John C Thompson; Enrico Caserta; Hui Wang; Jean-Leon Chong; Shan Naidu; Guo Wei; Sudarshana M Sharma; Julie A Stephens; Soledad A Fernandez; Metin N Gurcan; Michael B Weinstein; Sanford H Barsky; Lisa Yee; Thomas J Rosol; Paul C Stromberg; Michael L Robinson; Francois Pepin; Michael Hallett; Morag Park; Michael C Ostrowski; Gustavo Leone Journal: Nature Date: 2009-10-22 Impact factor: 49.962
Authors: Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi Journal: PLoS Biol Date: 2008-12-02 Impact factor: 8.029
Authors: Margarita Bartish; Dongmei Tong; Yangxun Pan; Majken Wallerius; Hui Liu; Johannes Ristau; Sabrina de Souza Ferreira; Tatjana Wallmann; Vincent van Hoef; Laia Masvidal; Thomas Kerzel; Anne-Laure Joly; Christophe Goncalves; Samuel E J Preston; Talin Ebrahimian; Christina Seitz; Jonas Bergh; Kristian Pietras; Stephanie Lehoux; Luigi Naldini; John Andersson; Mario Leonardo Squadrito; Sonia V Del Rincón; Ola Larsson; Charlotte Rolny Journal: Proc Natl Acad Sci U S A Date: 2020-10-19 Impact factor: 11.205
Authors: Brian J Sandri; Gabriele R Lubach; Eric F Lock; Michael K Georgieff; Pamela J Kling; Christopher L Coe; Raghavendra B Rao Journal: J Nutr Date: 2020-04-01 Impact factor: 4.798
Authors: Brian J Sandri; Jonathan Kim; Gabriele R Lubach; Eric F Lock; Candace Guerrero; LeeAnn Higgins; Todd W Markowski; Pamela J Kling; Michael K Georgieff; Christopher L Coe; Raghavendra B Rao Journal: Am J Physiol Regul Integr Comp Physiol Date: 2022-03-10 Impact factor: 3.210
Authors: Brian J Sandri; Jonathan Kim; Gabriele R Lubach; Eric F Lock; Candace Guerrero; LeeAnn Higgins; Todd W Markowski; Pamela J Kling; Michael K Georgieff; Christopher L Coe; Raghavendra B Rao Journal: Data Brief Date: 2022-09-11